An update on tenapanor to treat hyperphosphatemia.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.1.3343689
Abstract: Hyperphosphatemia is a common feature in patients with chronic kidney disease (CKD), especially in those with end-stage renal disease (ESRD). Commonly, high serum phosphate levels are observed only in later stages of CKD. The control… read more here.
Keywords: phosphate; phosphate levels; update tenapanor; hyperphosphatemia ... See more keywords